Abstract: A method for manufacturing a skin chip according to an exemplary embodiment of the present disclosure may include: a step of forming first and second PDMS layers disposed on both surfaces of a porous membrane and each having a microfluidic channel through which a culture medium is transferred to both surfaces of the porous membrane; a step of forming first and second MEA substrate layers disposed on the outer surfaces of the first and second PDMS layers, respectively, and having metal electrodes for measurement of TEER arranged at positions corresponding to the channels; and a step of forming first and second PMMA layers disposed on the outer surfaces of the first and second MEA substrate layers, respectively. In the method for manufacturing a skin chip according to in an exemplary embodiment of the present disclosure, the porous membrane may be made of a polycarbonate having pores of a predetermined size.

Abstract: The present disclosure provides host cells for reliable, high yield recombinant protein production, including unstable proteins. The present host cell (e.g., a bacterial cell) is deficient in at least one protease (or a subunit of a protease) such as Clp or ClpP. The host cell may also contain an expression vector that encodes a protein or polypeptide for overexpression.

Abstract: The present disclosure provides an innovative method for improving the enzyme activity of an NMN biosynthetic enzyme Nampt, and relates to the technical field of genetic engineering. A mutant protein of the present disclosure is obtained by firstly analyzing a target protein Nampt using two softwares FoldX and DeepDDG, and then predicting multiple key sites influencing the enzyme functions and finally performing the semi-rational design of the enzyme. In the examples of the present disclosure, 10 mutant strains are constructed using the designed primers according to the principle of point mutation, and 8 of the mutants have higher activity than a wild-type strain, in which the NMN yield of the mutant Nampt-V365L is increased by 62%, and the NMN yields of the mutants Nampt-S248A, Nampt-N164L, Nampt-S382M, Nampt-A245T and Nampt-A208G are increased by 34%, 27%, 27%, 22% and 17% respectively.

Abstract: The present invention relates to an alkoxyphenyl derivative capable of synthesizing an oligonucleotide by a quicker liquid phase synthesis method than in the prior art, a protected nucleoside and a protected nucleotide to which the alkoxyphenyl derivative is bonded, a method for producing an oligonucleotide using the same, and a method for selectively removing the alkoxyphenyl derivative moiety and the like. A compound represented by the general formula (1) or a derivative thereof: (In the formula, R each independently represents an optionally substituted alkyl group having 10 to 40 carbons. m represents an integer between 1 and 5. When m is 2 or more, a plurality of ROs may be the same or different. X represents O, S, NH, or NRN. n represents an integer from 1 to 4. RN represents an optionally substituted alkyl group having 1 to 6 carbons.

Abstract: In one aspect, the present disclosure provides a formulation comprising a hyaluronidase enzyme and a therapeutically effective amount of an active ingredient. In another aspect, the present disclosure provides a method of administering a high volume of the formulation in a single administration to treat a disease or disorder in a subject.

Abstract: The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts.

Abstract: The present invention relates to a method for the diagnosis of tumoural conditions and/or of the corresponding state of advance, wherein a sample from a patient comprising at least one tumour cell is obtained. According to the invention, a purified specimen of the at least one tumour cell is obtained by individually selecting and isolating single cells in a microfluidic device the purified specimen having a purity of at least 90%. On the purified specimen thus obtained there is subsequently performed a molecular analysis such as to highlight a characteristic thereof suited to enabling diagnosis.

Abstract: Methods and systems are provided for generating and utilizing a genetically engineered bacterium comprising a modification in glnD, wherein said modification is selected from the group consisting of: deletion of the entire gene, deletion of substantially the entire gene, deletion of an ACT domain, deletion of more than 50% of an ACT domain, deactivation of an ACT domain, and deactivation of an UTase domain.

Abstract: Provided herein are methods of organic waste stream conversion including fermenting an organic waste stream with an inoculum using arrested methanogenesis to generate an organic product. The inoculum includes an anaerobic consortium isolated from cheese, yogurt, saline soil, kefir, and/or probiotics and the anaerobic consortium is pretreated to transform the anaerobic consortium into an acidogenic consortium.

Abstract: A method for drying high protein products of ethanol fermentation such as high protein thin stillage by combining wet high protein product with dry high protein product and passing the combined high protein product through a venturi.

Abstract: The present invention provides a mutated histidine decarboxylase suitable for a practical use. Specifically, the present invention provides a mutated histidine decarboxylase having at least one amino acid residue mutated as compared to a wild-type histidine decarboxylase, and having higher histidine decarboxylase activity and/or stability than the wild-type histidine decarboxylase, and also a use thereof. The mutated histidine decarboxylase has Motifs (1) to (6), and an amino acid residue in at least one motif thereof can be mutated. The mutated histidine decarboxylase can also have a mutation of at least one amino acid residue in an amino acid sequence designated by SEQ ID NO: 3 and in a homologous sequence thereto.

Abstract: Described are compositions and methods relating to enzyme-containing, hot-melt-prepared granules produced from a starting material that contains an amount of water sufficient to denature the enzyme under hot-melt processing conditions. The resulting granules are particularly useful in consumer and industrial products, such as detergent, animal feed, food, personal care and agricultural compositions.

Abstract: Disclosed herein are processes for ethanol production from a lignocellulosic feedstock. These processes provide DMR of lignocellulosic biomass comprising two-stage deacetylation followed by mechanical refining so as to increase fermentable sugar yield while reducing hydrolytic enzyme loading requirements.

Abstract: An R-3-aminobutyric acid preparation method with high efficiency and high stereoselectivity. The method comprises using aspartase with stereoisomerization catalytic activity derived from Escherichia coli to efficiently convert butenoic acid into R-3-aminobutyric acid. After only 24 h of reaction, the conversion rate is as high as ?98%, and the ee value is ?99.9%. The conversion efficiency is greatly improved, the reaction time is shortened, and the production costs are reduced. The method features a high yield, a high conversion rate, low costs, a short production cycle, a simple process, ease of enlargement, suitability for mass production and the like.

Abstract: Methods, compositions, and cells for generating acyl alcohols. Compositions comprising acyl alcohols. Methods of cleaving acyl amino acids and/or acyl alcohols to generate free fatty acids, free amino acids, and/or free alcohols.

Abstract: The present disclosure relates to non-naturally occurring polypeptides useful for preparing Ezetimibe, polynucleotides encoding the polypeptides, and methods of using the polypeptides.

Abstract: Provided is a method of anaerobically fermenting a gaseous substrate to form a liquid product, the method comprising: (a) introducing the gaseous substrate into a bio-reactor, the gaseous substrate comprising at least one of the following constituents: carbon monoxide, carbon dioxide, and hydrogen, (b) the bio-reactor comprising a fermentation broth therein, the fermentation broth containing at least two types of microorganisms, one type comprising at least one fermenting species, and the other type comprising at least one competing species; (c) introducing at least one type of ionophore into the reactor, the ionophore having selectivity for preferentially inhibiting the at least one competing species from growing and/or producing an undesired product; and (d) allowing the gaseous substrate to ferment by exposure to the at least one fermenting species, to produce the liquid product and a system for doing the same.

Abstract: The present disclosure relates to the biosynthesis of indigoid dye precursors and their conversion to indigoid dyes. Specifically, the present disclosure relates to methods of using polypeptides to produce indigoid dye precursors from indole feed compounds, and the use of the indigoid dye precursors to produce indigoid dyes.

Abstract: An object of the present invention is to provide a novel method capable of producing rosuvastatin calcium and intermediates therefor efficiently, inexpensively and with high purity. The present invention provides a method of efficiently producing rosuvastatin calcium and intermediates therefor having a high purity at an industrial scale, without using an extremely low temperature reaction or a special asymmetric catalyst.

Abstract: The instant disclosure is generally related to novel engineered (hybrid) promoters. In certain embodiments, the instant disclosure is directed to one or more nucleic acid compositions comprising engineered promoters operably linked to nucleic acids encoding proteins of interest. Thus, the disclosure set forth herein described methods and compositions for the production of proteins of interest using one or more novel engineered (hybrid) promoters of the disclosure.